1. Home
  2. Labeler Index
  3. Remedyrepack Inc.
  4. 70518-3195
  5. Product Images: Desvenlafaxine

Product Images Desvenlafaxine

View Photos of Packaging, Labels & Appearance

Product Label Images

The following 7 images provide visual information about the product associated with Desvenlafaxine NDC 70518-3195 by Remedyrepack Inc., such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

Remedy_Label - Remedy Label

Remedy_Label - Remedy Label

Desvenlafaxine is the active ingredient in this extended-release tablet. It contains 25 mg and comes in a quantity of 90. The NDC number is 70518-3195-00 and the manufacturer is Slate Run Pharmaceuticals located in Columbus, Ohio. Keep it out of the reach of children and store it between 20-26°C (63-77°F) with permitted excursions to 15-30°C (59-86°F) [See USP]. There are no directions for use available, so refer to the package insert. This particular product was repackaged by RemedyRepack Inc. located in Indiana, PA 15701.*

chemical structure - des structure

chemical structure - des structure

figure 1 - figure 1

figure 1 - figure 1

This is a table describing the geometric mean ratio (with 90% confidence intervals) of maximum concentration (Cmax) and area under the curve (AUC) for a drug in different populations. The populations include those with varying degrees of renal and hepatic impairment, as well as gender and age groups (65-75 years and >75 years). "ESRD" refers to End Stage Renal Disease.*

figure 2 - figure 2

figure 2 - figure 2

This appears to be a table showing changes in Cmax (maximum concentration of a drug in the bloodstream) due to the effect of CYP3A4 inhibitors, specifically Ketoconazole. The table includes geometric mean ratios with 90% confidence intervals for both the Ketoconazole and reference (no inhibitor) conditions. The values in the table are likely related to pharmacokinetic (PK) studies of the drug under different conditions.*

figure 3 - figure 3

figure 3 - figure 3

The text refers to PK geometric mean ratios (90% ClI) related to interacting drugs, showing changes in Desvenlafaxine's CYP substrates' levels such as desipramine, midazolam, tamoxifen, and aripiprazole. The results show relative changes in Cmax and AUC values for varying doses of Desvenlafaxine and the interacting drugs.*

figure-4 - figure 4

figure-4 - figure 4

This is a graph displaying the estimated proportion of patients with relapse over time measured in days from randomization. The graph includes two lines, one for Desvenlafaxine Extended-Release Tablets and one for Placebo. The percentage of patients with relapse is shown on the y-axis and the time to relapse is shown on the x-axis. The Desvenlafaxine Extended-Release Tablets line is not completely visible in the given snippet, but appears to show a lower proportion of patients with relapse compared to the Placebo line.*

figure-5 - figure 5

figure-5 - figure 5

This is a graph displaying the estimated proportion of patients experiencing relapse over time in days from randomization, comparing Desvenlafaxine Extended-Release Tablets and Placebo. The x-axis represents time (in days) up to 150, and the y-axis represents the estimated proportion of patients with relapse expressed in percentage (%). The graph shows that Desvenlafaxine has a lower relapse rate compared to Placebo.*

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.